How to Get Prescribed Semaglutide Online: A Step-by-Step Guide

The question isn't whether telehealth can replace in-person care for GLP-1 prescriptions — for the vast majority of patients, it already has. Major academic medical centers, insurance-covered plans, and direct-to-patient telehealth platforms now routinely handle GLP-1 weight-loss consultations online. What patients researching this for the first time often don't know is what the actual process involves, what qualifies them, and critically, how to distinguish a compliant provider from the growing number of non-compliant ones.

This guide walks through each step, in order.

Step 1: Understanding the Eligibility Criteria

GLP-1 medications are not available to everyone who wants them. The FDA approval criteria for weight management use of semaglutide (Wegovy) are specific:

The weight-related comorbidities that qualify under the BMI ≥27 threshold include: high blood pressure (hypertension), type 2 diabetes or prediabetes, dyslipidemia (abnormal cholesterol or triglycerides), and obstructive sleep apnea. These are the comorbidities specifically listed in the Wegovy FDA labeling.

Who Is Not Eligible

There are absolute contraindications that a physician will screen for before prescribing semaglutide:

• Personal or family history of medullary thyroid carcinoma (MTC) — a rare thyroid cancer
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Personal history of pancreatitis
• Known hypersensitivity to semaglutide or any component of the formulation
• Pregnancy or planning to become pregnant

Patients with type 1 diabetes, severe kidney disease, or certain cardiac conditions may also face additional scrutiny or require specialist involvement. A thorough prescriber will assess all of these — this is a core function of the medical evaluation, not a formality.

Step 2: The Online Health Assessment

Every legitimate telehealth GLP-1 program begins with a structured health intake. This is not a marketing form — it is the clinical data collection step that allows the physician to make a prescribing decision. What you'll typically be asked to provide:

• ✓Basic demographics: Age, sex, height, weight (to calculate BMI)
• ✓Current health conditions: Hypertension, diabetes, dyslipidemia, sleep apnea, thyroid disorders, kidney disease, liver disease, and others — both to assess eligibility and screen for contraindications
• ✓Current medications: Essential for detecting interactions, particularly with insulin, sulfonylureas (other diabetes medications), and blood pressure medications that may interact with weight loss
• ✓Relevant medical history: Prior diagnosis of pancreatitis, thyroid cancer, MEN2, eating disorders, or bariatric surgery
• ✓GLP-1 history: Whether you've previously used Ozempic, Wegovy, Mounjaro, or similar medications — and how you responded
• ✓Weight history and goals: Highest and lowest adult weight, prior weight-loss attempts, and treatment goals
• ✓Consent and legal acknowledgments: Telehealth consent, treatment consent, acknowledgment of risks

A well-designed intake takes about 10 minutes. Platforms that collect this information completely are giving their physicians what they need to prescribe safely. Platforms that skip or abbreviate this step are a red flag — more on that below.

Step 3: The Physician Consultation

This is where legal telehealth prescription differs fundamentally from a non-compliant one: a licensed physician must actually review your case and make an independent clinical judgment before any prescription is issued.

In most telehealth weight-loss programs, this takes one of two forms:

Both models are legally valid. The async model is more common in direct-to-patient platforms because it's faster and doesn't require scheduling — without sacrificing the physician review that makes it compliant. PropPilot uses the async model, with board-certified physicians reviewing submissions and responding within 24 hours.

What the Physician Is Evaluating

During the review — whether async or live — the physician is making specific clinical determinations:

• Does this patient meet FDA-approved eligibility criteria for weight-management semaglutide?
• Are there any contraindications that make prescribing unsafe?
• Are there drug interactions with current medications that require dose adjustments or additional monitoring?
• What starting dose and titration schedule is appropriate for this patient?
• Does this patient understand the treatment plan, including what to expect with side effects?

The prescription is the output of this evaluation — not a default that happens after form submission. If a platform issues prescriptions to all applicants without any reported rejections or follow-up questions, that is a signal the review process may not be functioning as it should.

Step 4: The Prescription and Pharmacy Fulfillment

If the physician approves the prescription, it is sent electronically to a pharmacy. The pharmacy options vary by platform:

• Major retail pharmacies (CVS, Walgreens, Rite Aid, Walmart) — standard option; requires insurance or out-of-pocket payment at standard retail pricing
• Mail-order / specialty pharmacies — often partnered directly with the telehealth platform; may include medication delivery to your door
• Compounding pharmacies — produce non-brand-name semaglutide compounded formulations; see important note below

Insurance and Cost

Insurance coverage for Wegovy (weight management) remains limited — most commercial plans do not cover it, though coverage is expanding. Ozempic has broader coverage for patients with a type 2 diabetes diagnosis. For a detailed breakdown of costs and coverage options, including manufacturer savings programs and telehealth pricing models, see our semaglutide cost guide.

Step 5: Ongoing Care and Follow-Up

GLP-1 treatment is not a one-time prescription — it involves a titration schedule that typically spans 16–20 weeks to reach the full therapeutic dose, and ongoing prescribing thereafter for patients who continue treatment. A compliant telehealth program includes:

• 1
  Dose escalation review At each dose step, the physician or clinical team should confirm tolerability and determine whether to escalate. Most programs do this via check-in messages or follow-up assessments at 4-week intervals.
• 2
  Side effect management access Patients who experience significant side effects should be able to reach their prescribing physician or a clinical team member for guidance. Platforms with no pathway for this are not providing complete care.
• 3
  Prescription renewal Monthly refills require ongoing clinical oversight. Reputable platforms confirm continued eligibility and monitor for any new contraindications before refilling.
• 4
  Lab monitoring recommendations Depending on your health profile, your physician may recommend baseline labs (HbA1c, lipid panel, kidney function) and periodic monitoring. This is not universally required for all patients but is standard for those with relevant comorbidities.

Telehealth vs In-Person: What's the Actual Difference?

For most patients who meet eligibility criteria and have no complicating health factors, telehealth provides equivalent access to prescribing with meaningfully fewer logistical barriers. In-person care has advantages for patients with complex medical histories where a physical examination may inform prescribing decisions — or for patients who prefer an integrated relationship with a single physician managing their overall health.

Red Flags: Sites to Avoid

The rapid growth of GLP-1 prescribing has produced a significant number of non-compliant services operating outside the legal and regulatory framework for telehealth prescribing. These represent real risks — both to patient safety and, in some states, legal exposure for obtaining controlled or prescription medications without a valid prescription.

Specific warning signs in practice:

• A "questionnaire" that is 2–3 questions and takes less than 2 minutes
• No mention of a prescribing physician anywhere on the platform
• Guaranteed approval language ("Start today — no rejection") before any evaluation
• No prescription required, or "OTC semaglutide" — there is no such thing in the United States
• No telehealth consent form or HIPAA notice
• No physical address or state licensing information for the prescribers listed

The FTC and FDA have both issued guidance specifically addressing deceptive telehealth prescribing practices. Patients who obtain prescriptions through non-compliant channels may receive medications of unverified quality and have no legal recourse if harm results.

PropPilot's Approach: Compliant Telehealth Across All 50 States

PropPilot connects patients with board-certified physicians licensed in all 50 states. Every prescription issued through our platform follows the same process described above: a structured health intake, independent physician review of your full health history, and a prescribing decision made by a licensed physician — not an algorithm, not a form approval flow.

We prescribe FDA-approved medications filled through licensed pharmacies. Our physicians review each submission and respond within 24 hours. For patients who do not meet eligibility criteria or who have contraindications, we communicate that clearly — rather than approving everyone who applies.

What we do not do: guarantee prescriptions before evaluation, skip the physician review step, or source medications from unverified channels.

If you're ready to find out whether you qualify, the eligibility assessment takes about 10 minutes. For more background on how GLP-1 medications work and what clinical outcomes look like, see What Are GLP-1 Medications? For an evidence-based overview of side effects and how to manage them, see our semaglutide side effects guide. For a head-to-head comparison of Ozempic, Wegovy, and Mounjaro, see Ozempic vs Wegovy vs Mounjaro.